Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Immuneering Corp Cl A (IMRX)

Immuneering Corp Cl A (IMRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Can Immuneering's Pancreatic Cancer Survival Data Turn Market Skepticism Into Conviction? Barchart - Sun May 10, 4:00PM CDT

Barchart Research What to Expect from IMRX Earnings IMRX Generated May 8, 2026 Current Price $5.22 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Can Immuneering's Pancreatic Cancer...

IMRX : 5.14 (-4.46%)
Can Immuneering's Pancreatic Cancer Survival Data Turn Market Skepticism Into Conviction? Barchart - Sat May 9, 4:00PM CDT

Barchart Research What to Expect from IMRX Earnings IMRX Generated May 8, 2026 Current Price $5.22 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Can Immuneering's Pancreatic Cancer...

IMRX : 5.14 (-4.46%)
Can Immuneering's Pancreatic Cancer Survival Data Turn Market Skepticism Into Conviction? Barchart - Fri May 8, 4:06PM CDT

Barchart Research What to Expect from IMRX Earnings IMRX Generated May 8, 2026 Current Price $5.22 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Can Immuneering's Pancreatic Cancer...

IMRX : 5.14 (-4.46%)
Immuneering's Pancreatic Cancer Data Could Finally Answer Whether Survival Translates to Pivotal Trial Momentum Barchart - Sun May 3, 4:00PM CDT

Barchart Research What to Expect from IMRX Earnings IMRX Generated May 1, 2026 Current Price $5.38 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Immuneering's Pancreatic Cancer Data...

IMRX : 5.14 (-4.46%)
Immuneering's Pancreatic Cancer Data Could Finally Answer Whether Survival Translates to Pivotal Trial Momentum Barchart - Sat May 2, 4:00PM CDT

Barchart Research What to Expect from IMRX Earnings IMRX Generated May 1, 2026 Current Price $5.38 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Immuneering's Pancreatic Cancer Data...

IMRX : 5.14 (-4.46%)
Immuneering's Pancreatic Cancer Data Could Finally Answer Whether Survival Translates to Pivotal Trial Momentum Barchart - Fri May 1, 4:07PM CDT

Barchart Research What to Expect from IMRX Earnings IMRX Generated May 1, 2026 Current Price $5.38 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Immuneering's Pancreatic Cancer Data...

IMRX : 5.14 (-4.46%)
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting GlobeNewswire - Tue Apr 21, 3:05PM CDT

- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health - - The ASCO presentation...

IMRX : 5.14 (-4.46%)
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond GlobeNewswire - Mon Apr 20, 8:00AM CDT

Analysis of circulating tumor DNA from atebimetinib-treated patients shows acquired MAPK pathway alterations are rare, supporting observed durable first-line activity Atebimetinib-treated tumors...

IMRX : 5.14 (-4.46%)
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference GlobeNewswire - Mon Apr 6, 3:05PM CDT

NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced...

IMRX : 5.14 (-4.46%)

Barchart Exclusives

Cisco (CSCO) Stock Just Hit a Record High Amid Layoffs Announcement Barchart - 44 minutes ago
Cisco shares rallied on blowout Q3 earnings and a new round of layoffs affecting nearly 4,000 jobs. Morgan Stanley analysts continue to see CSCO stock as “cheap” at current levels. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.